The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
The Smith Institute for Urology at Northwell Health, Lake Success, NY, USA.
BJU Int. 2023 Jun;131(6):763-769. doi: 10.1111/bju.15979. Epub 2023 Mar 23.
To develop and validate the Pelvic Pain Map to fill a gap in the need for a localised body map of the pelvic region.
The Pelvic Pain Map incorporated input from 12 chronic pelvic pain experts across the United States, as well as patient feedback to assess face validity. Finalised diagrams are single, front-facing images of the male and female pelvis that incorporate both abdominal and perineal views. Assessment of test-retest reliability and construct (convergent and discriminant) validity was carried out on a retrospective cohort of patients with chronic pelvic pain syndrome (CPPS) who completed the maps from January 2022 to May 2022. Other measures used in the validation process consisted of the male and female forms of the Genitourinary Pain Index (GUPI) and the short form (six item) of the Pain Catastrophising Scale (PCS-6).
Test-retest for individual map zones demonstrated moderate to excellent reliability (Cohen's kappa coefficients ranging from 0.28 to 0.64) and for total map zones demonstrated excellent reliability (intraclass correlation coefficient = 0.90). Convergent validity for individual map zones with location descriptors from the GUPI was strong (phi coefficients ranging from 0.26 to 0.79) and for total map zones was moderate (Spearman's correlation coefficient = 0.56). Discriminant validity for total map zones with separate, but related constructs from the GUPI and PCS-6 was weakly positive (Spearman's correlation coefficients ranging from 0.27 to 0.32).
This study suggests that the Pelvic Pain Map is a valid and reliable tool for assessing location of pain in patients with CPPS. Our findings highlight the potential utility of the Pelvic Pain Map in guiding treatment selection and monitoring therapeutic response in patients with chronic pelvic pain.
开发和验证盆腔疼痛图，以填补盆腔区域局部化身体图谱的需求空白。
盆腔疼痛图整合了来自美国 12 位慢性盆腔疼痛专家的意见以及患者的反馈，以评估表面效度。最终的图表是男性和女性骨盆的单一、正面图像，包含腹部和会阴视图。对 2022 年 1 月至 2022 年 5 月期间完成图谱的慢性盆腔疼痛综合征（CPPS）患者回顾性队列进行了测试-再测试可靠性和结构（收敛和判别）有效性评估。验证过程中使用的其他措施包括男性和女性形式的泌尿生殖疼痛指数（GUPI）和疼痛灾难化量表（PCS-6）的简短形式（六项）。
个体图谱区域的测试-再测试显示出中度至极好的可靠性（Cohen's kappa 系数范围为 0.28 至 0.64），而总图谱区域显示出极好的可靠性（组内相关系数= 0.90）。个体图谱区域与 GUPI 位置描述符的收敛效度较强（phi 系数范围为 0.26 至 0.79），总图谱区域的收敛效度为中度（Spearman 相关系数= 0.56）。总图谱区域与 GUPI 和 PCS-6 的单独但相关结构的判别效度为弱阳性（Spearman 相关系数范围为 0.27 至 0.32）。
本研究表明，盆腔疼痛图是一种评估 CPPS 患者疼痛部位的有效且可靠的工具。我们的研究结果强调了盆腔疼痛图在指导慢性盆腔疼痛患者的治疗选择和监测治疗反应方面的潜在效用。
